Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × talazoparib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 12 Pancreatic Neoplasms 3 Breast Neoplasms 3 Sarcoma, Ewing 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Prostate Cancer Metastatic 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Kidney Neoplasms 1 Hepatoblastoma 1 Fanconi Anemia, Complementation Group D1 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Adenocarcinoma 1

Interventions

pembrolizumab 76 Gemcitabine 48 Nivolumab 41 Cisplatin 35 atezolizumab 34 Carboplatin 27 avelumab 25 enfortumab vedotin 23 Docetaxel 22 Magnetic Resonance Spectroscopy 17 Paclitaxel 15 Ipilimumab 15 Mitomycin 14 Specimen Handling 12 durvalumab 10 toripalimab 9 sacituzumab govitecan 9 Pemetrexed 8 vinflunine 7 cabozantinib 7 Taxes 7 Injections 6 Cyclophosphamide 6 Bevacizumab 6 tislelizumab 5 pemigatinib 5 Standard of Care 5 Fluorodeoxyglucose F18 5 Biopsy 5 lenvatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04678362 2025-09-22

TALASUR

Centre Francois Baclesse

Phase 2 Recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡